Triphase, Celgene deal

Triphase said Celgene exercised its option to acquire proteasome inhibitor marizomib (NPI-0052). Triphase will receive an undisclosed upfront payment and is eligible for milestones. Celgene will be responsible for further development and will fund Triphase's ongoing trials of the candidate...